UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 126

Sortiert nach

Nerve growth factor signaling and Its contribution to pain

Journal of pain research, 2020-01, Vol.13, p.1223-1241, Article 1223

2020

Volltextzugriff (PDF)

Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety

Pain (Amsterdam), 2019-10, Vol.160 (10), p.2210-2220

2019

Volltextzugriff (PDF)

The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia

European urology, 2013-03, Vol.63 (3), p.506-516

2013

Volltextzugriff (PDF)

Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study

The Journal of urology, 2008-10, Vol.180 (4), p.1228-1234

2008

Volltextzugriff (PDF)

Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men

International journal of urology, 2013-02, Vol.20 (2), p.193-201

2013

Volltextzugriff (PDF)

Long‐Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial

Arthritis & rheumatology (Hoboken, N.J.), 2021-07, Vol.73 (7), p.1167-1177

2021

Volltextzugriff (PDF)

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

Pain (Amsterdam), 2020-09, Vol.161 (9), p.2068-2078

2020

Volltextzugriff (PDF)

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

BMC musculoskeletal disorders, 2022-02, Vol.23 (1), p.106-106, Article 106

2022

Volltextzugriff (PDF)

The not so hidden impact of interictal burden in migraine: A narrative review

Frontiers in neurology, 2022-11, Vol.13, p.1032103-1032103

2022

Volltextzugriff (PDF)

Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study

Arthritis research & therapy, 2022-03, Vol.24 (1), p.78-13, Article 78

2022

Volltextzugriff (PDF)

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action

Neurourology and urodynamics, 2011-03, Vol.30 (3), p.292-301

2011

Volltextzugriff (PDF)

Factors associated with physician-reported treatment status of patients with osteoarthritis pain

BMC musculoskeletal disorders, 2022-05, Vol.23 (1), p.498-498, Article 498

2022

Volltextzugriff (PDF)

The risk of lower urinary tract symptoms five years after the first delivery

Neurourology and urodynamics, 2002, Vol.21 (1), p.2-29

Viktrup, Lars

2002

Volltextzugriff (PDF)

Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

BMC urology, 2012-11, Vol.12 (1), p.30-30, Article 30

2012

Volltextzugriff (PDF)

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1‐year, open‐label extension study

BJU international, 2011-04, Vol.107 (7), p.1110-1116

2011

Volltextzugriff (PDF)

Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea

International journal of urology, 2014-07, Vol.21 (7), p.670-675

2014

Volltextzugriff (PDF)

Efficacy and safety of tadalafil 5 mg once‐daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double‐blind, parallel, placebo‐ and tamsulosin‐controlled study

International journal of urology, 2019-02, Vol.26 (2), p.192-200

2019

Volltextzugriff (PDF)

Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action

Therapeutic Advances in Urology, 2015-10, Vol.7 (5), p.249-264

2015

Volltextzugriff (PDF)

Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis

Advances in rheumatology (London, England), 2024-04, Vol.64 (1), p.31-5, Article 31

2024

Volltextzugriff (PDF)

Incidence and Remission of Lower Urinary Tract Symptoms During 12 Years After the First Delivery: A Cohort Study

The Journal of urology, 2008-09, Vol.180 (3), p.992-997

2008

Volltextzugriff (PDF)

Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo

International journal of urology, 2015-06, Vol.22 (6), p.582-587

2015

Volltextzugriff (PDF)

Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons

Journal of clinical medicine, 2023-01, Vol.12 (2), p.589

2023

Volltextzugriff (PDF)

Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction

Journal of clinical medicine, 2023-04, Vol.12 (7), p.2733

2023

Volltextzugriff (PDF)

Response to: "Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis"

Journal of anaesthesiology, clinical pharmacology, 2018-10, Vol.34 (4), p.548-548

2018

Volltextzugriff (PDF)

A retrospective pooled analysis of duloxetine safety in 23 983 subjects

Current medical research and opinion, 2007-01, Vol.23 (1), p.175-184

2007

Volltextzugriff (PDF)

1 – 25 von 126

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(95)

Publikationsform

Artikel
(125)
magazinearticle
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Nerve growth factor signaling and Its contribution to pain

Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety

The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia

Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study

Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men

Long‐Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

The not so hidden impact of interictal burden in migraine: A narrative review

Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action

Factors associated with physician-reported treatment status of patients with osteoarthritis pain

The risk of lower urinary tract symptoms five years after the first delivery

Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1‐year, open‐label extension study

Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea

Efficacy and safety of tadalafil 5 mg once‐daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double‐blind, parallel, placebo‐ and tamsulosin‐controlled study

Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action

Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis

Incidence and Remission of Lower Urinary Tract Symptoms During 12 Years After the First Delivery: A Cohort Study

Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons

Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and Satisfaction

Response to: "Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis"

A retrospective pooled analysis of duloxetine safety in 23 983 subjects

Suchergebnisse filtern